As of September 18, 2026, ACUTAAS is trading at ₹3440.3, showing a mixed technical picture across different timeframes. The daily timeframe indicates a bearish Super Trend signal, with the price below this indicator, despite the price being above key moving averages like the 20-day and 50-day Exponential Moving Averages (EMAs) and Simple Moving Averages (SMAs). This suggests potential short-term weakness or consolidation. In contrast, the weekly and monthly timeframes display bullish Super Trend signals, with the price trading above these indicators, indicating a stronger underlying uptrend on longer durations. Recent active weekly patterns include a Hammer and an Inside Bar, which can sometimes signal trend continuation or reversal.

The stock is currently positioned near its nearest resistance level at ₹3444.07, approximately 0.11% above the current price. Key support is observed around ₹3405.03, about 1.03% below the current price. The stock has experienced an extreme volume anomaly on September 10, 2026, with a significant price increase and a volume ratio of 3.78, indicating heightened activity. The annualized volatility stands at 0.42, with a current drawdown of -0.07 and a maximum drawdown of -0.18, suggesting moderate risk.

Key conditions to monitor include a sustained break above the ₹3444.07 resistance level, which could reinforce the longer-term bullish trend. Conversely, a decisive move below the ₹3405.03 support level, especially on increased volume, might signal a weakening of the weekly and monthly uptrends and a potential continuation of the daily bearish signal.

Acutaas Chemicals was highlighted in market commentary on September 18, 2026, with one report suggesting a 'buy' at ₹3,315, anticipating upward movement towards ₹4,000. This commentary noted the stock had reached a record high of ₹3,735 in early July before consolidating, with a support base identified between ₹3,000 and ₹3,050. The company was also listed among several others scheduled to trade ex-dividend on September 17, 2026.

Acutaas Chemicals (NSE: ACUTAAS) has seen recent discussion around its stock performance, with one report on 2026-09-18 noting a previous record high of ₹3,735 reached in early July. Following this peak, the stock reportedly lost momentum and entered a consolidation phase, though the uptrend is considered intact as long as the ₹3,000-3,050 price band acts as support. The current price on 2026-09-18 was ₹3,440.3, an increase from the previous price of ₹3,315.1. Another report from the same date suggested an expectation of upward momentum towards ₹4,000.

What remains unchanged is the company's profile as Acutaas Chemicals listed on the NSE.

Acutaas Chemicals Limited has announced several developments impacting its operational capacity and strategic initiatives. On August 22, 2026, the company's board approved a significant capital expenditure of up to ₹212 crore for a new plant in Gujarat, intended to produce electronic grade chemicals with a proposed capacity of up to 81,000 metric tons per annum, targeted for completion by the end of fiscal year 2027-28. This expansion is supported by an incentive package under the Electronics Components Manufacturing Scheme (ECMS) for its Electrolyte Additives business in Jhagadia, Gujarat, where the cumulative project investment is ₹256.47 crore, with ₹119.12 crore eligible for incentives up to 25% during the benefit period ending FY 2030-31. Further enhancing its R&D capabilities, Acutaas inaugurated a new Pilot Plant at its Sachin, Surat facility on September 4, 2026, designed to support new product trials and validations, including a dedicated area for Occupational Exposure Band (OEB) 4 containment for developing high potency intermediates. The company also reported on September 10, 2026, that the Patent Office of India granted it a 20-year process patent for 'A PROCESS FOR PREPARING 2,4-DIMETHYLTHIOPHENOL,' effective from September 21, 2017, bringing its total granted patents to 11. Additionally, a step-down subsidiary, Indichem Inc., inaugurated a semiconductor chemicals manufacturing plant in Gongju, South Korea, on August 28, 2026, with Acutaas Advance Material Limited (AAML) holding a 75% stake and having invested approximately ₹200 crore in the venture.

Acutaas Chemicals has demonstrated a significant upward trajectory in its financial performance, with reported sales growing from ₹717 crore in FY2024 to a projected ₹1,339 crore by FY2026. This growth is accompanied by a substantial improvement in operating profit, which is expected to increase from ₹128 crore in FY2024 to ₹480 crore by FY2026. The company's operating profit margin (OPM) is also projected to expand considerably, from 18.0% in FY2024 to an anticipated 36.0% in FY2026. Earnings per share (EPS) have shown a strong recovery, rising from ₹5.80 in FY2024 to a projected ₹43.51 by FY2026.

Financially, the company's balance sheet shows a notable increase in Fixed Assets from ₹427 crore in FY2024 to a projected ₹745 crore by FY2026, alongside a significant rise in Construction Work in Progress (CWIP) from ₹125 crore to ₹332 crore over the same period. This expansion is financed by a substantial increase in borrowings, which rose from ₹217 crore in FY2024 to a projected ₹13 crore in FY2025, and then to ₹36 crore in FY2026, alongside a growing equity base. Cash flow from operations has also seen a positive trend, increasing from ₹125 crore in FY2024 to a projected ₹292 crore in FY2026. However, free cash flow has remained negative, projected to be ₹-36 crore in FY2026, indicating that operational cash generation is not yet sufficient to cover investing activities.

Key monitoring areas include the continued expansion of sales and operating margins, the management of borrowings and their impact on finance costs, and the generation of positive free cash flow. The increasing investments in fixed assets and CWIP suggest ongoing capital expenditure, which will be important to track for future returns. Shareholding patterns show a decrease in promoter holding from 39.91% in March 2024 to a projected 32.66% by March 2026, while FIIs and DIIs have increased their stakes.

Acutaas Chemicals has demonstrated significant growth in key financial metrics. Over the last five years, the company has achieved a compounded sales growth of 32% and a compounded profit growth of 46%. This trend has accelerated in the Trailing Twelve Months (TTM) period, with sales growing by 41% and profits by 104%. The company's operational efficiency is reflected in its cash flow from operations, which increased from ₹15 crore in March 2019 to ₹27 crore in March 2020. Free cash flow also turned positive, moving from -₹7 crore in March 2019 to ₹6 crore in March 2020. The balance sheet shows an increase in reserves from ₹72 crore in March 2019 to ₹101 crore in March 2020, alongside a rise in fixed assets from ₹79 crore to ₹85 crore, indicating investment in operational capacity. Concurrently, total liabilities decreased from ₹213 crore to ₹232 crore, while total assets grew from ₹213 crore to ₹232 crore.

Acutaas Chemicals shows an increase in borrowings from ₹54 crore in March 2019 to ₹59 crore in March 2020. Concurrently, its Capital Work-In-Progress (CWIP) significantly rose from ₹2 crore to ₹12 crore over the same period, indicating increased investment in ongoing projects. While total assets grew to ₹232 crore in March 2020 from ₹213 crore in March 2019, this expansion was accompanied by a rise in total liabilities. The company's cash flow from financing activities was ₹0.0 in March 2020, a decrease from ₹6.0 in March 2019, suggesting a reduced reliance on external financing for that period. The daily trend analysis indicates a bearish supertrend direction as of September 18, 2026, with an ADX of 14.93, suggesting a lack of strong directional momentum.